Search Results
Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL
Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
Dr. Goy Compares Acalabrutinib With Ibrutinib in MCL
Dr. Goy on Future Treatment Approaches in MCL
Venetoclax Plus Ibrutinib Combo Shows Potential in Relapsed/Refractory MCL
Dr. Goy on Takeaways in Mantle Cell Lymphoma for the Future
Dr. Goy on Changing Treatment Landscape of Mantle Cell Lymphoma
Dr. Goy on Bortezomib in MCL Treatment
Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL
Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017
Prof John Gribben and Prof Andre Goy at ASH 2014: Treating mantle cell lymphoma (Part 2)
Dr. Andre Goy & Dr. Andrew Pecora, J. Michael Armstrong & Tomas Gregorio
